The Vancouver-based firm is forming the Next Generation Psychedelic Research Advisory Board with Wells as its first member, according to a statement Thursday.
Wells brings over 20 years of experience in the psychedelics space, working with molecules and looking at the therapeutic benefits for mental health disorders. Her research appeared in the Multidisciplinary Association for Psychedelic Studies and she currently serves as co-director of Breaking Convention, Europe’s largest conference on psychedelic consciousness.
READ: BetterLife Pharma seeks patent protection for new 2-Bromo-LSD formulations to treat depression and mood disorders
Wells has worked with Amnesty International, Transform Drug Policy Foundation, The International Center for Ethnobotanical Education, Research, and Service (ICEERS), the Global Diversity Foundation, and The Joint Nature Conservation Committee and Centre for Biocultural Diversity. She holds an MSc in Ethnobotany from the University of Kent, and BSc in Social Anthropology from The London School of Economics.
“We welcome Hattie Wells to advise and assist our team in developing the next generation psychedelic products,” BetterLife CEO Ahmad Doroudian said in a statement.
“Her more than 20 years of experience in this field is a great addition to our clinical and regulatory team as we continue to advance our plans in developing our products to treat mental health disorders and become the leader in the psychedelic space.”
BetterLife is focused on the development and commercialization of next generation psychedelic products for the treatment of mental disorders.
Contact Angela at email@example.com
Follow her on Twitter @AHarmantas